-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical equipment is an indispensable equipment in the pharmaceutical production process
.
In recent years, with the rapid development of the pharmaceutical industry, the domestic pharmaceutical equipment market has also grown, and the current scale has reached 100 billion yuan
.
In the long run, under the background of the accelerated transformation and upgrading of the pharmaceutical industry and the rapid development of emerging pharmaceutical industries such as biopharmaceuticals, it is expected that the domestic pharmaceutical machine market will approach 200 billion yuan in 2025
.
The blue ocean of the domestic pharmaceutical equipment market has emerged, but there are still some bottlenecks in the process of embracing opportunities for domestic pharmaceutical equipment companies.
The industry believes that at least four challenges need to be addressed
.
Pharmaceutical equipment (Source: Pharmaceutical Network) First, there is a shortage of compound talents in the pharmaceutical equipment industry, and the professional teaching level needs to be improved urgently
.
At present, the domestic pharmaceutical equipment industry, including the entire manufacturing industry, has a bottleneck of talent shortage, and companies generally cannot recruit people.
This is mainly related to various factors such as salary and welfare, social status, and work intensity
.
A pharmaceutical machine person pointed out that in the pharmaceutical machine industry, pharmaceutical machine companies at this stage need compound talents who understand both pharmaceuticals and equipment operation.
Such talents are more difficult to find than ordinary technical talents
.
"In addition, the standard of teaching in many majors is also low, which cannot meet the needs of pharmaceutical machine manufacturers for high-level talents
.
" How to solve the shortage of talents is a big challenge
.
At present, domestic pharmaceutical machine giants, including Chutian and Tofflon, have made various "moves" to recruit and retain talents, such as increasing wages, improving employees' living and working conditions,
etc.
Looking at the entire industry, what the industry calls more is to improve the traditional talent training model, innovate the talent training model that combines production, education and research, and strengthen policy support
.
Second, there is still competition among small and medium-sized pharmaceutical machine companies to lower prices
.
There are thousands of pharmaceutical machine enterprises in China, but most of them are small and medium-sized.
At present, the products of most enterprises are mainly based on low-level repeated production
.
In the face of an increasingly competitive market, vicious competition among enterprises and competitive price reductions occur frequently, hindering the healthy and stable development of the entire pharmaceutical machine market and the principle of fair competition. .
High-level domestic medicine machine products are scarce, which is not conducive to technological innovation and technological progress in the industry
.
Therefore, with the emergence of a blue ocean in the domestic pharmaceutical machine market, domestic pharmaceutical machine companies also need to strengthen technological innovation, increase investment in research and development, build high-level equipment, and create strong market competitiveness
.
Third, some pharmaceutical machine manufacturers often deviate from the actual production of pharmaceuticals when conducting product research and development
.
Pharmaceutical machines are used by pharmaceutical manufacturers, and equipment that is separated from the actual production of pharmaceuticals cannot meet the actual production needs of pharmaceutical companies, and may even have some problems, resulting in economic losses
.
Therefore, domestic pharmaceutical machine companies need to carry out product research and development around the actual production of drugs to meet the actual production needs of pharmaceutical companies, in order to help the better development of the pharmaceutical industry
.
Fourth, pharmaceutical machine companies ignore the small test and test links
.
Small test, test and production are all closely related parts.
Among them, small test is mainly for exploratory and developmental work, while pilot test is a preliminary enlargement of small test and a preliminary attempt of small production.
Reliable experimental data to help production
.
At the same time, during the pilot test process, the process can be further revised to remove some parts that are not suitable for the production of pharmaceutical companies, and then develop a process suitable for production
.
The industry pointed out that for large-scale production pharmaceutical companies, the importance of small scale and pilot scale is more prominent, they can provide reliable process means and data basis for large-scale production, and avoid problems such as waste
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In recent years, with the rapid development of the pharmaceutical industry, the domestic pharmaceutical equipment market has also grown, and the current scale has reached 100 billion yuan
.
In the long run, under the background of the accelerated transformation and upgrading of the pharmaceutical industry and the rapid development of emerging pharmaceutical industries such as biopharmaceuticals, it is expected that the domestic pharmaceutical machine market will approach 200 billion yuan in 2025
.
The blue ocean of the domestic pharmaceutical equipment market has emerged, but there are still some bottlenecks in the process of embracing opportunities for domestic pharmaceutical equipment companies.
The industry believes that at least four challenges need to be addressed
.
Pharmaceutical equipment (Source: Pharmaceutical Network) First, there is a shortage of compound talents in the pharmaceutical equipment industry, and the professional teaching level needs to be improved urgently
.
At present, the domestic pharmaceutical equipment industry, including the entire manufacturing industry, has a bottleneck of talent shortage, and companies generally cannot recruit people.
This is mainly related to various factors such as salary and welfare, social status, and work intensity
.
A pharmaceutical machine person pointed out that in the pharmaceutical machine industry, pharmaceutical machine companies at this stage need compound talents who understand both pharmaceuticals and equipment operation.
Such talents are more difficult to find than ordinary technical talents
.
"In addition, the standard of teaching in many majors is also low, which cannot meet the needs of pharmaceutical machine manufacturers for high-level talents
.
" How to solve the shortage of talents is a big challenge
.
At present, domestic pharmaceutical machine giants, including Chutian and Tofflon, have made various "moves" to recruit and retain talents, such as increasing wages, improving employees' living and working conditions,
etc.
Looking at the entire industry, what the industry calls more is to improve the traditional talent training model, innovate the talent training model that combines production, education and research, and strengthen policy support
.
Second, there is still competition among small and medium-sized pharmaceutical machine companies to lower prices
.
There are thousands of pharmaceutical machine enterprises in China, but most of them are small and medium-sized.
At present, the products of most enterprises are mainly based on low-level repeated production
.
In the face of an increasingly competitive market, vicious competition among enterprises and competitive price reductions occur frequently, hindering the healthy and stable development of the entire pharmaceutical machine market and the principle of fair competition. .
High-level domestic medicine machine products are scarce, which is not conducive to technological innovation and technological progress in the industry
.
Therefore, with the emergence of a blue ocean in the domestic pharmaceutical machine market, domestic pharmaceutical machine companies also need to strengthen technological innovation, increase investment in research and development, build high-level equipment, and create strong market competitiveness
.
Third, some pharmaceutical machine manufacturers often deviate from the actual production of pharmaceuticals when conducting product research and development
.
Pharmaceutical machines are used by pharmaceutical manufacturers, and equipment that is separated from the actual production of pharmaceuticals cannot meet the actual production needs of pharmaceutical companies, and may even have some problems, resulting in economic losses
.
Therefore, domestic pharmaceutical machine companies need to carry out product research and development around the actual production of drugs to meet the actual production needs of pharmaceutical companies, in order to help the better development of the pharmaceutical industry
.
Fourth, pharmaceutical machine companies ignore the small test and test links
.
Small test, test and production are all closely related parts.
Among them, small test is mainly for exploratory and developmental work, while pilot test is a preliminary enlargement of small test and a preliminary attempt of small production.
Reliable experimental data to help production
.
At the same time, during the pilot test process, the process can be further revised to remove some parts that are not suitable for the production of pharmaceutical companies, and then develop a process suitable for production
.
The industry pointed out that for large-scale production pharmaceutical companies, the importance of small scale and pilot scale is more prominent, they can provide reliable process means and data basis for large-scale production, and avoid problems such as waste
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.